North Hills Medical Research Inc | North Richland Hills, TX

Research site

Location

4351 Booth Calloway Road suite 304, North Richland Hills, Texas, United States of America

Site insights

Top conditions

Top treatments

Tirzepatide

LY3298176

Orforglipron

Dapagliflozin

BMS-512148

LY3502970

Bococizumab

indapamide

amlodipine

telmisartan

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

ted melliza

Verified by this site

Active trials

9 of 27 total trials

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a fram...

Enrolling

Hypertension

Drug: Orforglipron

Drug: Placebo

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hy...

Enrolling

Hypertension

Overweight or Obesity

Drug: Placebo

Drug: Orforglipron

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment...

Enrolling

Hypertension

Drug: Orforglipron

Drug: Placebo

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: Tirzepatide

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. (AFFIRM)

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Active, not recruiting

Crohn's Disease

Drug: Placebo for risankizumab

Drug: Risankizumab SC

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopa...

Enrolling

Idiopathic Gastroparesis

Drug: Placebo

Drug: CIN-102 Dose 15mg

A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)

The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who, despite taking 2 or more antihy...

Active, not recruiting

Hypertension

Drug: Tonlamarsen

Drug: Placebo

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Obicetrapib

Drug: Placebo

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of car...

Enrolling

Overweight

Atherosclerotic Cardiovascular Disease

Drug: Maridebart Cafraglutide

Drug: Placebo